Futility analysis augurs defeat in pivotal trial testing of NuCana's lead drug in metastatic pancreatic cancer

Futility analysis augurs defeat in pivotal trial testing of NuCana's lead drug in metastatic pancreatic cancer

Source: 
Endpoints
snippet: 

Nearly two years after making its public debut, UK-based NuCana’s mission to make chemotherapies more potent and safer was dealt a blow, after a pivotal study testing its lead experimental drug halted enrollment in a hard-to-treat advanced form of cancer, following a futility analysis.